CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
CytoDyn has appointed Richard Pestell, M.D., Ph.D. as Lead Consultant in Preclinical and Clinical Oncology. Dr. Pestell, who previously served as Vice Chairman and CMO, will lead the company's R&D strategy in oncology for leronlimab development. He brings over 30 years of research experience and currently serves as President of the Pennsylvania Cancer and Regenerative Medicine Research Center. During his previous tenure at CytoDyn, he was instrumental in obtaining FDA Fast Track Designation for leronlimab in combination with carboplatin for CCR5-positive metastatic triple-negative breast cancer treatment. Dr. Pestell's work includes over 600 publications with more than 95,000 citations.
CytoDyn ha nominato Richard Pestell, M.D., Ph.D. come Consulente Principale per l'Oncologia Preclinica e Clinica. Il Dr. Pestell, che in precedenza ha ricoperto il ruolo di Vice Presidente e CMO, guiderà la strategia R&D dell'azienda in oncologia per lo sviluppo di leronlimab. Porta con sé oltre 30 anni di esperienza nella ricerca e attualmente è Presidente del Pennsylvania Cancer and Regenerative Medicine Research Center. Durante il suo precedente mandato in CytoDyn, è stato determinante per ottenere la Designazione Fast Track della FDA per leronlimab in combinazione con carboplatino per il trattamento del carcinoma mammario triplo negativo metastatico positivo CCR5. Il lavoro del Dr. Pestell comprende oltre 600 pubblicazioni con più di 95.000 citazioni.
CytoDyn ha nombrado a Richard Pestell, M.D., Ph.D. como Consultor Principal en Oncología Preclínica y Clínica. El Dr. Pestell, quien anteriormente se desempeñó como Vicepresidente y CMO, liderará la estrategia de I+D de la compañía en oncología para el desarrollo de leronlimab. Aporta más de 30 años de experiencia en investigación y actualmente es Presidente del Centro de Investigación en Cáncer y Medicina Regenerativa de Pensilvania. Durante su anterior mandato en CytoDyn, fue fundamental para obtener la Designación Fast Track de la FDA para leronlimab en combinación con carboplatino para el tratamiento del cáncer de mama triple negativo metastásico positivo para CCR5. El trabajo del Dr. Pestell incluye más de 600 publicaciones con más de 95,000 citas.
CytoDyn은 Richard Pestell, M.D., Ph.D.를 전임 컨설턴트로 임명했습니다. Dr. Pestell은 이전에 부회장과 CMO로 재직했으며, 렐론리맙 개발을 위한 회사의 R&D 전략을 이끌 것입니다. 그는 30년 이상의 연구 경험을 가지고 있으며 현재 펜실바니아 암 및 재생 의학 연구 센터의 회장으로 활동하고 있습니다. CytoDyn에서의 이전 재임 기간 동안 그는 CCR5 양성 전이성 삼중 음성 유방암 치료를 위한 카보플라틴과의 병용 요법에 대한 렐론리맙의 FDA 신속 심사 지정을 받는 데 중요한 역할을 했습니다. Dr. Pestell의 연구업적은 600편 이상의 논문과 95,000회 이상의 인용을 포함합니다.
CytoDyn a nommé Richard Pestell, M.D., Ph.D. en tant que consultant principal en oncologie préclinique et clinique. Le Dr Pestell, qui a précédemment occupé le poste de vice-président et CMO, dirigera la stratégie R&D de l'entreprise en oncologie pour le développement de leronlimab. Il apporte plus de 30 ans d'expérience en recherche et est actuellement président du Pennsylvania Cancer and Regenerative Medicine Research Center. Durant son précédent mandat chez CytoDyn, il a joué un rôle crucial dans l'obtention de la désignation Fast Track de la FDA pour leronlimab en combinaison avec le carboplatine pour le traitement du cancer du sein triple négatif métastatique positif CCR5. Le travail du Dr Pestell comprend plus de 600 publications avec plus de 95 000 citations.
CytoDyn hat Richard Pestell, M.D., Ph.D. zum Hauptberater für präklinische und klinische Onkologie ernannt. Dr. Pestell, der zuvor als stellvertretender Vorsitzender und CMO tätig war, wird die R&D-Strategie des Unternehmens in der Onkologie für die Entwicklung von leronlimab leiten. Er bringt über 30 Jahre Forschungserfahrung mit und ist derzeit Präsident des Pennsylvania Cancer and Regenerative Medicine Research Center. Während seiner vorherigen Amtszeit bei CytoDyn spielte er eine entscheidende Rolle beim Erhalt der FDA Fast Track-Designierung für leronlimab in Kombination mit Carboplatin zur Behandlung von CCR5-positivem metastasierendem triple-negativem Brustkrebs. Die Arbeiten von Dr. Pestell umfassen über 600 Publikationen mit mehr als 95.000 Zitierungen.
- Previous success in obtaining FDA Fast Track Designation for leronlimab in breast cancer treatment
- Appointment of highly qualified expert with over 30 years of research experience
- Strong track record in oncology research with over 600 publications and 95,000 citations
- Prior experience with the company and familiarity with leronlimab development
- None.
VANCOUVER, Washington, Nov. 25, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Richard Pestell, M.D., Ph.D., has been appointed as Lead Consultant, Preclinical and Clinical Oncology. Dr. Pestell will lead the Company’s research and development strategy in oncology and utilize his expertise and vast network to further CytoDyn’s clinical evaluation of the capabilities for leronlimab in cancer treatment.
Dr. Pestell brings over three decades of in-depth research experience to the CytoDyn team, with robust expertise investigating novel drug products and therapies. He is currently the President of the Pennsylvania Cancer and Regenerative Medicine Research Center, a part of the Baruch S. Blumberg Institute in Doylestown, Pennsylvania. Prior to this role, he spent a decade at Thomas Jefferson University in Philadelphia, Pennsylvania, serving as Director of the Sidney Kimmel Cancer Center, Chairman of the Department of Cancer Biology and Executive Vice President. Dr. Pestell’s work has been published in over 600 publications, and his research has been credited with well over 95,000 citations. He previously served as Vice Chairman of the Board, and Chief Medical Officer (CMO), spearheading the Company’s successful effort to obtain Fast Track Designation from the FDA for the use of leronlimab in combination with carboplatin for the treatment of patients with CCR5-positive metastatic triple-negative breast cancer. In addition, Dr. Pestell was instrumental in designing and initiating CytoDyn’s Phase 1b/2 clinical trial in that indication.
“I’m thrilled to welcome Dr. Pestell back to the CytoDyn team. I have known Dr. Pestell personally for a number of years, and I look forward to leveraging his insights and expertise to advance our clinical development pipeline in oncology,” said Dr. Jacob Lalezari, CEO. “As we continue to prioritize the development of leronlimab in oncology, Dr. Pestell’s expertise will help CytoDyn maximize opportunities to pursue breakthrough treatment in a variety of cancer indications.”
Dr. Pestell added, “I am confident that leronlimab holds significant promise for improving patient care and expanding treatment options in oncology. I am eager to support the Company’s efforts to advance our clinical development pipeline and leverage the potential of leronlimab to improve outcomes for cancer patients.”
Dr. Pestell holds a medical degree from the University of Western Australia, and a Ph.D. from the University of Melbourne, Howard Florey Institute. He conducted clinical training in oncology and endocrinology and was inducted as a Fellow of the Royal Australian College of Physicians. His postdoctoral research at the Harvard School of Medicine and Massachusetts General Hospital with Dr. Larry Jameson focused on endocrine oncology. He completed his executive MBA at New York University’s Stern School of Business in 2011. Dr. Pestell has received numerous awards for his research discoveries including elected membership to ASCI (American Society of Clinical Investigation), Elected Member of the Royal Society of Medicine, Elected Fellow of the American Association for the Advancement of Science, the RD Wright Medallion, the Eric Susman Prize in Medicine, Advance Global Australian Award (Biotechnology), a Doctor of Medical Sciences, HonorisCausa, from the University of Melbourne and awards from Susan G. Komen (Light of Life award, Jamie Brooke Lieberman Award). Dr. Pestell received the Order of Australia (AO) in 2019 from Queen Elizabeth II and was elected as a Member of the Academia Europaea in 2024.
About CytoDyn
CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. Leronlimab is being studied for oncology and inflammation, as well as other potential indications.
Note Regarding Forward-Looking Statements
This news release contains forward-looking statements relating to, among other things, clinical drug development and research strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2024, including the section captioned “Forward-Looking Statements,” and in Part I, Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statements as a result of new information or future events or developments other than as required by law.
Media Contacts
CytoDyn
Riyaz Lalani
Gagnier Communications
CytoDyn@gagnierfc.com
FAQ
What is Richard Pestell's new role at CytoDyn (CYDY)?
What was Dr. Pestell's previous achievement at CytoDyn (CYDY)?
What is leronlimab being developed for by CytoDyn (CYDY)?
